Related Experiment Videos
Technology evaluation: MLN-591, Cornell University/BZL Biologics/ImmunoGen/Millennium
Christian Doehn1, Dieter Jocham
1Department of Urology, University of Lübeck Medical School, Ratzeburger Allee 160, 23538 Lübeck, Germany. doehn@medinf.mu-luebeck.de
Current Opinion in Molecular Therapeutics
|February 25, 2003
Abstract:
MLN-591 is a monoclonal antibody specific for prostate-specific membrane antigen that is being developed by Cornell University, BZL Biologics, ImmunoGen Inc and Millennium Pharmaceuticals Inc for the potential treatment of prostate cancer. MLN-591 was in phase II trials by May 2002.